New pill for relapsed T-cell large granular lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage study tests a new pill (zeprumetostat) for people with a rare type of leukemia (T-LGLL) that has not improved after initial treatment. The goal is to see if it can safely improve blood counts and relieve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL).
- You have symptoms like low blood counts, an enlarged spleen, or an autoimmune condition that needs treatment.
- You have already tried and not responded to or couldn't tolerate a first treatment.
- You are generally able to care for yourself (ECOG score 0–2) and expected to live at least 6 more months.
- You do not have another active cancer, a history of organ/stem cell transplant, or serious organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zeprumetostat (an EZH2 inhibitor) combined with other treatments for people with mature T-cell or NK-cell lymphoma that has come back or not responded to standard therapy. The goal is to see if the combination can help control the lymphoma.
This study tests a new drug, zeprumetostat, combined with other treatments for people with a type of lymphoma that has come back or not responded to previous therapy. The goal is to see if these combinations can help control the cancer.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hear when a new T-LGL Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.